Sale!

Fungal Candida Multiplex Detection & Differentiation RNA Detection Qualitative Test

Original price was: $426.Current price is: $362.

-15%

The Fungal Candida Multiplex Detection & Differentiation RNA Detection Qualitative Test is a cutting-edge diagnostic tool that identifies and differentiates between eight clinically significant Candida species using advanced RNA detection technology. This comprehensive test detects C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei, C. nivariensis, C. dubliniensis, and Clavispora lusitaniae with exceptional accuracy. It’s particularly valuable for patients with suspected systemic fungal infections, immunocompromised individuals, and those not responding to initial antifungal therapy. The test provides rapid results within 36-48 hours, enabling timely and targeted treatment decisions. Priced at $362 USD, this advanced molecular test offers superior sensitivity compared to traditional culture methods and helps guide appropriate antifungal therapy selection based on species-specific resistance patterns.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Fungal Candida Multiplex Detection & Differentiation RNA Detection Qualitative Test

Comprehensive Candida Species Identification for Accurate Diagnosis

The Fungal Candida Multiplex Detection & Differentiation RNA Detection Qualitative Test represents a significant advancement in molecular diagnostics for fungal infections. This sophisticated test utilizes Real-Time PCR technology to simultaneously detect and differentiate eight clinically relevant Candida species from various clinical specimens. By targeting RNA rather than DNA, this test provides enhanced sensitivity and specificity, making it an invaluable tool for healthcare providers managing patients with suspected or confirmed fungal infections.

What This Test Measures and Detects

Our advanced multiplex test specifically identifies and differentiates the following Candida species:

  • Candida albicans – The most common cause of human candidiasis
  • Candida glabrata – Known for reduced susceptibility to fluconazole
  • Candida tropicalis – Associated with higher mortality rates in bloodstream infections
  • Candida parapsilosis – Common in catheter-related infections
  • Candida krusei – Intrinsically resistant to fluconazole
  • Candida nivariensis – A recently identified species with potential resistance patterns
  • Candida dubliniensis – Often misidentified as C. albicans
  • Clavispora lusitaniae – Known for developing resistance during antifungal therapy

Who Should Consider This Test

This comprehensive Candida detection test is recommended for patients experiencing:

  • Persistent fever unresponsive to antibacterial therapy
  • Immunocompromised conditions (HIV/AIDS, chemotherapy, organ transplantation)
  • Unexplained sepsis or bloodstream infections
  • Recurrent oral or genital candidiasis
  • Hospital-acquired infections with risk factors for invasive candidiasis
  • Patients with central venous catheters or other medical devices
  • Individuals not responding to initial antifungal treatment
  • Suspected disseminated candidiasis with multi-organ involvement

Clinical Benefits of Candida Multiplex Testing

Choosing our comprehensive Candida multiplex test offers numerous advantages:

  • Rapid Results: Receive test results within 36-48 hours compared to traditional culture methods that can take several days
  • Species-Specific Identification: Accurate differentiation enables targeted antifungal therapy selection
  • Enhanced Sensitivity: RNA detection provides superior sensitivity, especially in patients receiving antifungal treatment
  • Resistance Pattern Guidance: Species identification helps predict potential antifungal resistance patterns
  • Comprehensive Coverage: Simultaneous detection of eight clinically significant species in a single test
  • Multiple Sample Types: Testing available from blood, BAL, tissue biopsies, and various clinical specimens

Understanding Your Test Results

Your test results will provide clear information about which Candida species, if any, were detected in your sample:

  • Positive Result: Indicates the presence of one or more Candida species, with specific identification of which species were detected
  • Negative Result: Suggests no detectable Candida RNA in the tested sample
  • Species-Specific Report: Detailed identification of exactly which Candida species are present
  • Clinical Correlation: Results should be interpreted in the context of clinical symptoms and other laboratory findings

It’s important to discuss your results with your healthcare provider, who will consider your specific clinical situation, symptoms, and other diagnostic findings to determine the most appropriate treatment plan.

Test Pricing Information

Test Name Regular Price Discount Price
Fungal Candida Multiplex Detection & Differentiation RNA Detection Qualitative Test $426 USD $362 USD

Convenient Testing Locations Across the USA

GGC DNA has testing facilities conveniently located throughout the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures accessible testing services for patients across the country.

Book Your Test Today

Take control of your health with our advanced Candida multiplex detection test. Early and accurate identification of Candida species can significantly impact treatment outcomes and recovery. Our experienced genetic counselors and healthcare professionals are available to answer your questions and guide you through the testing process.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or to speak with one of our genetic specialists. We’re committed to providing you with the highest quality diagnostic services and personalized care.

Note: This test requires signing a consent document and bringing any relevant clinical history for the patient. Sample types accepted include blood, BAL, fresh tissue biopsy specimens, skin biopsy specimens from patients with disseminated nodular skin lesions, tissue specimens from various body sites, peripheral blood specimens, and respiratory secretions.